. Author manuscript; available in PMC: 2022 Jan 10.

Published in final edited form as: Prog Neuropsychopharmacol Biol Psychiatry. 2020 Jul 16;104:110041. doi: 10.1016/j.pnpbp.2020.110041

Table 1:

Newer agents that are under scanner for drug development

Drugs	Site of Action	Uses
Ketamine	NMDA receptor antagonist	Anesthesia, inhibits painful sensations, antidepressant
R025-6981	Specific antagonist of NMDA receptor 2B subtype (NR2B)	Antidepressant
SSR125543	CRF1 receptor antagonist	Antidepressant and anxiolytic
NBI-30775 and NBI34041	CRF1 receptor antagonist	Anxiety; Depression; Irritable bowel syndrome
RU486 (mifepristone), Org34116, Org 34517, Org34850	Pituitary glucocorticoid receptor (GR) antagonists	Functional impairments in the depressed brain, especially in the hippocampus
AZD-7268	Delta opioid receptor agonists	Antidepressant
LY2456302	κ opioid receptor antagonist	Major depressive disorder and substance use disorders including alcoholism, nicotine addiction, and illicit drug dependence
Mecamylamine	Nicotinic acetylcholine receptors (nAChRs) antagonist	Antidepressant
GSK0660	PPARγ antagonist	Anxiolytic, antidepressant, and antiobesity effects
Rolipram	Selective phosphodiesterase-4 inhibitor	Autoimmune diseases, Alzheimer’s disease, cognitive enhancement, spinal cord injury, and respiratory diseases
Roflumilast (Daxas, Daliresp)	Selective, long-acting inhibitor of the enzyme phosphodiesterase-4	Severe chronic obstructive pulmonary disease